{"id":"Z14","lang":"zh","question":"永昕生醫在做什麼？它的生物藥 CDMO 和台康生技差在哪？","answer":[{"text":"永昕官網將公司定位為生物藥 CDMO，服務包括可開發性評估、細胞株與製程開發、GMP 生產及法規文件。","fact_ids":["f1"]},{"text":"永昕也列出抗體、linker-payload 與 ADC 的委託開發製造；台康的公司介紹則明列 CDMO 與產品開發並行的雙軌模式。","fact_ids":["f2","f3"]}],"facts":[{"id":"f1","claim":"永昕服務","value":"評估、細胞株、製程、GMP生產、法規文件","as_of":"2026-10-22","source":"https://www.mycenax.com/about.php?id=28&lang=en","quote":"regulatory documents"},{"id":"f2","claim":"永昕ADC服務","value":"抗體、linker-payload與ADC開發製造","as_of":"2026-10-22","source":"https://mycenax.com/cdmo.php?id=56","quote":"antibodies, linkers-payloads, and ADCs"},{"id":"f3","claim":"台康營運模式","value":"CDMO與產品開發並行","as_of":"2026-08-28","source":"https://www.formosapharma.com/formosa-pharmaceuticals-files-clinical-trial-application-for-tsy-110-an-antibody-drug-conjugate-biosimilar-targeting-her2-positive-breast-cancers/","quote":"combining CDMO with Product Development"}],"undisclosed":{"text":"本卡核對的兩家公司公開介紹沒有提供可直接同口徑比較的報價、交期或各客戶專案臨床階段。","source":"https://www.mycenax.com/about.php?id=28&lang=en","as_of":"2026-10-22","quote":"biopharmaceutical services and solutions","scope":"Only the specific primary documents cited in this card were checked; absence is not a claim about all public disclosures."},"verified_at":"2026-10-22","coverage":"partial","limitations":["可比的是公開服務與營運模式；價格、交期與同口徑產能比較查無。"]}